Le Lézard
Classified in: Health
Subjects: NPT, POL, PSF

Sleep first. Drive alert. Drowsy Driving Prevention Week® 2021


WASHINGTON, Nov. 5, 2021  /PRNewswire/ -- The National Sleep Foundation (NSF) announces November 7-14 as Drowsy Driving Prevention Week® for 2021.

Drowsy Driving Prevention Week® is a time to reflect on how dangerously common?but preventable?drowsy driving truly is. Drowsy driving can be avoided. The most important preventative measure to stopping drowsy driving is a well-rested driver.

Drowsy driving is responsible for more than 6,400 U.S. deaths annually and is a public health concern. Younger drivers aged 16-25 are at greatest risk of falling asleep at the wheel, but almost everyone can relate to a time when they have nodded off behind the wheel. The National Highway Traffic Safety Administration estimates that 100,000 police reported crashes each year are caused primarily by drowsy driving and that such crashes result in more than 71,000 injuries and $12.5 million in monetary losses. Most importantly, drowsy driving is preventable. NSF's annual campaign goal is to reduce the number of drivers who drive while sleep deprived.

"Drowsy driving is a public health issue that can affect everyone. NSF encourages all drivers to prioritize sleep and drive only when alert and refreshed," said NSF Chair, Lauren Hale, PhD.

The NSF Drowsy Driving Consensus Working Group's 2016 report published in Sleep Health concluded that sleep deprivation renders motorists unfit to drive a motor vehicle.1 Specifically, healthy drivers who have slept for two hours or less in the preceding 24 hours are not fit to operate a motor vehicle. NSF experts further agreed that most healthy drivers would likely be impaired with only 3 to 5 hours of sleep during the prior 24 hours.

Three key steps before driving can help prevent falling asleep behind the wheel:

Join NSF to help prevent drowsy driving. Access educational resources today on theNSF.org and share the campaign's message on social media using the hashtag #SleepFirst.

NSF is proud to recognize Jack Cooper, Schneider National and Waymo as Drowsy Driving Prevention Week sponsors and demonstrating their commitment to sleep health and road safety. We're also pleased that the Drowsy Driving Prevention Project and National Safety Council are joining NSF to help educate the public about the dangers of drowsy driving.

References
1. National Sleep Foundation. Drowsy Driving Consensus Workgroup. Nov. 2015. Czeisler, CA, Wickwire, EM, Barger LK, et al. Sleep-deprived motor vehicle operators are unfit to drive: a multidisciplinary expert consensus statement on drowsy driving. Sleep Health. 2016;2(2):94-99.

About the National Sleep Foundation
The National Sleep Foundation (NSF) is a 501(c)3 nonprofit corporation dedicated to improving health and well-being through sleep education and advocacy. Founded in 1990, the NSF is committed to advancing excellence in sleep health theory, research and practice. theNSF.org ?SleepHealthJournal.org

SOURCE National Sleep Foundation


These press releases may also interest you

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: